Molecular mechanism of miRNA regulating PD-L1 expression

被引:0
作者
Zhao, Wenxin [1 ,2 ]
Li, Xiaolan [1 ,2 ]
Ren, Qunli [1 ,2 ]
Wang, Qian [1 ,2 ]
Liao, Chengcheng [2 ]
Ding, Tianhao [2 ]
Li, Ping [1 ]
Liu, Jianguo [2 ]
机构
[1] Zunyi Med Univ, Microbial Resources & Drug Dev Key Lab Guizhou Ter, Sch Stomatol, Zunyi 563000, Peoples R China
[2] Zunyi Med Univ, Sch Clin Med, Zunyi 563000, Peoples R China
来源
GENE REPORTS | 2023年 / 31卷
关键词
PD-L1; miRNA; Immune checkpoint; Molecular regulation; Tumor suppressor gene; BREAST-CANCER; TARGETS PD-L1;
D O I
10.1016/j.genrep.2023.101763
中图分类号
Q3 [遗传学];
学科分类号
071007 ; 090102 ;
摘要
PD-L1 (programmed death-ligand 1) binding to PD-1 (programmed cell death protein 1) reduces the proliferation of PD-1-positive cells, inhibits their cytokine secretion, and induces apoptosis. miRNA (microRNA) as an important regulator of gene expression, affects the performance of gene function. Similarly, the expression of PDL1 is also regulated by miRNA. miRNAs usually negatively regulate gene expression, however, is there positive regulation? We reviewed the molecular mechanisms of the positive and negative regulation of PD-L1 expression by miRNAs. miRNAs mainly indirectly and positively regulate PD-L1 expression through the regulation of tumor suppressor genes PTEN (phosphatase and tensin homolog) and LATS2 (large tumor suppressor kinase 2), oncogene YAP1 (Yes1 associated transcriptional regulator), DNA damage response protein Ku80 (80-kilodalton subunit of the Ku heterodimer protein), etc., while negative regulation is mainly achieved by miRNAs directly binding to the 3 & PRIME;-UTR (3 & PRIME; untranslated region) of PD-L1 mRNA. And this negative regulation can also be reversed by the negative regulation of miRNAs by RNA-binding protein LIN28 (protein lin-28) or circRNAs (circular RNA) such as cire0000284 and circ-CPA4. The revealing of this mechanism provides more references and strategies for immune checkpoint therapy of tumors.
引用
收藏
页数:5
相关论文
共 50 条
  • [31] PD-L1 expression in extrahepatic cholangiocarcinoma
    Walter, Dirk
    Herrmann, Eva
    Schnitzbauer, Andreas A.
    Zeuzem, Stefan
    Hansmann, Martin Leo
    Peveling-Oberhag, Jan
    Hartmann, Sylvia
    HISTOPATHOLOGY, 2017, 71 (03) : 383 - 392
  • [32] PD-L1 Expression in Ampullary Adenocarcinoma
    Siddiqui, Saima Haleem
    Kumari, Niraj
    Mishra, Shravan
    Radha, Paturu
    Mohindra, Samir
    Singh, Rajneesh K.
    Krishnani, Narendra
    INTERNATIONAL JOURNAL OF SURGICAL PATHOLOGY, 2024, 32 (02) : 263 - 272
  • [33] Clinical and molecular correlates of PD-L1 expression in patients with lung adenocarcinomas
    Schoenfeld, A. J.
    Rizvi, H.
    Bandlamudi, C.
    Sauter, J. L.
    Travis, W. D.
    Rekhtman, N.
    Plodkowski, A. J.
    Perez-Johnston, R.
    Sawan, P.
    Beras, A.
    Egger, J. V.
    Ladanyi, M.
    Arbour, K. C.
    Rudin, C. M.
    Riely, G. J.
    Taylor, B. S.
    Donoghue, M. T. A.
    Hellmann, M. D.
    ANNALS OF ONCOLOGY, 2020, 31 (05) : 599 - 608
  • [34] PD-L1 expression in sebaceous carcinomas
    Saliba, Maelle
    Shaheen, Muhammad
    El Hajj, Rana
    Abbas, Fatmeh
    Bashir, Shaarif
    Sheikh, Umer Nisar
    Mahfouz, Rami
    Loya, Asif
    Khalifeh, Ibrahim
    CANCER IMMUNOLOGY IMMUNOTHERAPY, 2021, 70 (07) : 1907 - 1915
  • [35] The miRNA and PD-1/PD-L1 signaling axis: an arsenal of immunotherapeutic targets against lung cancer
    Yadav, Ritu
    Khatkar, Rinku
    Yap, Kenneth C-H
    Kang, Chloe Yun-Hui
    Lyu, Juncheng
    Singh, Rahul Kumar
    Mandal, Surojit
    Mohanta, Adrija
    Lam, Hiu Yan
    Okina, Elena
    Kumar, Rajiv Ranjan
    Uttam, Vivek
    Sharma, Uttam
    Jain, Manju
    Prakash, Hridayesh
    Tuli, Hardeep Singh
    Kumar, Alan Prem
    Jain, Aklank
    CELL DEATH DISCOVERY, 2024, 10 (01)
  • [36] The mechanism of ABL1 upregulating the expression of PD-L1 and the therapeutic effect of PD-L1 and STAT3 inhibitors in lung adenocarcinoma
    Tang, Dongfang
    Jiang, Haoyao
    Li, Zhigang
    Gao, Wen
    Sun, Yifeng
    NEOPLASMA, 2021, 68 (03) : 472 - 481
  • [37] Relationship between the ultrasound features of different molecular subtypes of breast cancer and positive PD-1/PD-L1 expression
    Yan, Ruiqian
    Li, Haixia
    Gao, Junxi
    JOURNAL OF INTERNATIONAL MEDICAL RESEARCH, 2025, 53 (02)
  • [38] PD-1/PD-L1 in disease
    Kuol, Nyanbol
    Stojanovska, Lily
    Nurgali, Kulmira
    Apostolopoulos, Vasso
    IMMUNOTHERAPY, 2018, 10 (02) : 149 - 161
  • [39] Mithramycin suppresses tumor growth by regulating CD47 and PD-L1 expression
    Gong, Jianhua
    Ji, Yuying
    Liu, Xiujun
    Zheng, Yanbo
    Zhen, Yongsu
    BIOCHEMICAL PHARMACOLOGY, 2022, 197
  • [40] An alternatively spliced PD-L1 isoform PD-L1∆3, and PD-L2 expression in breast cancers: implications for eligibility scoring and immunotherapy response
    Didem Naz Dioken
    Ibrahim Ozgul
    Irem Yilmazbilek
    Mustafa Cengiz Yakicier
    Ezgi Karaca
    Ayse Elif Erson-Bensan
    Cancer Immunology, Immunotherapy, 2023, 72 : 4065 - 4075